Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hi-Tech lidocaine HCl Jelly, 2% receives FDA final approval
The company claims the jelly is a generic version of APP Pharmaceuticals’ Xylocaine. Lidocaine HCl jelly, 2% is indicated for the prevention and control of pain in procedures
The company claims the jelly is a generic version of APP Pharmaceuticals’ Xylocaine. Lidocaine HCl jelly, 2% is indicated for the prevention and control of pain in procedures
The result of the study suggested that the economic model evaluated patients in Canada who were treated with Dabigatran Etexilate compared to those treated with warfarin in both
The Omega Stent System incorporates a platinum chromium (PtCr) alloy designed for coronary stenting and is intended to provide interventional cardiologists an improved acute performance in treating patients
The FDA has pointed minor observations in the company’s seven facilities in Philadelphia and five at Lannett‘s wholly owned subsidiary, Cody Laboratories, a manufacturer/supplier of pain management pharmaceutical
IDT Biologika plans to build a new frozen storage area, a filling building for vaccines and several special warehouses. Additionally, the company also intends to expand research laboratory
The new US patent entitled, ‘Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases,’ would provide protection until 2023. Agennix chief financial officer Torsten Hombeck said
The FDA will complete the review by July 2011, as it needs more time to investigate the data submitted by Novartis in support of QAB149 NDA. The company’s
GW Pharma and Almirall have completed European Mutual Recognition Procedure (MRP) for Sativex in the treatment of spasticity due to Multiple Sclerosis (MS). The companies have already received
GLB333 helps to rebuild the damaged tissues, reduces inflammatory conditions and help to regenerate good and healthy muscle and soft tissues. National Pharma will use the worldwide license
The randomised four-arm Phase 1/2 study was designed to compare once- and twice-daily doses of ISV-303 versus Xibrom and DuraSite (vehicle), each administered twice-daily. The trial enrolled 169